Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Novartis
Takeda
Institut Paoli-Calmettes
Massachusetts General Hospital
Roswell Park Cancer Institute
Gamida Cell ltd
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
University of Rochester
Massachusetts General Hospital
M.D. Anderson Cancer Center
Brown University
Ohio State University Comprehensive Cancer Center
Novartis
Center for International Blood and Marrow Transplant Research
Centre Henri Becquerel
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Janssen Research & Development, LLC
H. Lee Moffitt Cancer Center and Research Institute
University Hospital, Brest
Incyte Corporation
University of Arizona
Novartis
M.D. Anderson Cancer Center
Massachusetts General Hospital
Thomas Jefferson University
Takeda
Constellation Pharmaceuticals
American University of Beirut Medical Center
Hospices Civils de Lyon
Janssen Research & Development, LLC
National Institutes of Health Clinical Center (CC)
Centre Hospitalier Universitaire, Amiens
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Centre Hospitalier Universitaire, Amiens
Ohio State University Comprehensive Cancer Center
PharmaEssentia Japan K.K.
Novartis
Shenzhen TargetRx, Inc.
Novartis
Incyte Corporation
Celgene
Masonic Cancer Center, University of Minnesota
Eulji University Hospital
Stanford University
M.D. Anderson Cancer Center
Protagonist Therapeutics, Inc.
Center for International Blood and Marrow Transplant Research